Gabeta, S., Norman, GL, Liaskos, C, Papamichalis, PA, Zografos, T, Garagounis, A, Rigopoulou, EI, Dalekos, GN. Diagnostic relevance and clinical significance of the new enhanced performance M2 ELISA for the detection of IgA and IgG antimitochondrial antibodies in primary biliary cirrhosis. J. Clin. Immunology, 2007; 27(4): 378-387.

Montano-Loza A, Czaja AJ, Carpenter HA, Piette A, Murphy D, Shums Z, Burlingame R, Norman GL. Frequency and significance of antibodies to cyclic citrullinated peptide in type 1 autoimmune hepatitis. Autoimmunity 39: 341-8, 2006.

Nakamura, M, Takii, Y, Mori,T, Komori,A, Yokoyama,T, Daikoku, M, Matsumoto,T,Migita,K, Yatsuhashi,H, Ishibashi,H, Masaki,N, Adachi,H, Watanabe,Y, Nakamure,Y, Takezaki,E, Harada,H,Sando,T, Saoshiro,T, Komatsu,T, Shimada,M, Hayashi,S, Kobayashi,M, Sodeyama,T, Muro,T, Masumoto,A, Sugi,Kazuhiro, Lee, L, Shums, Z, Norman, GL. Anti-gp210 antibody in combination with anti-centromere antibody may identify PBC patients who are at high risk for end-stage hepatic failure. American Assn for the Study of Liver Disease , Annual Meeting San Francisco, 2005. Hepatol 2005; 42 (4 suppl 1) 463A.

Milkiewicz,P, Buwaneswaran, HB, Lee, L, Coltescu,C, Shums,Z. Norman,GL, Heathcote,EJ. Value of "new" autoantibody testing in the differential diagnosis of autoimmune liver conditions. American Assn for the Study of Liver Disease.Annual Meeting,San Francisco,2205. Hepatol. 2005; 42(4 suppl 1) 292A.

Nakamura, M, Kondo, H, Mori, T, Komori, A, Matsuyama, M, Ito, M, Takii, Y, Koyabu, M, Yokoyama, T, Migita, K, Daikoku, M, Abiru, S, Yatsuhashi, H, Takezaki, E, Masaki, N, Sugi,K, Honda, K, Adachi, H, Nishi,H, Watanabe, Y, Nakamura, Y, Shimada, M, Komatsu,T, Saito, A, Saoshiro,T, Harada, H, Sodeyama, T, Hayashi, S, Masumoto,A, Sando,T, Yamamoto,T, Sakai,H,Kobayashi, M, Muro, T, Koga, M, Shums,Z, Norman, GL, Ishibashi,H. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 2007; Jan; 45(1):118-27. American Assn for the Study of Liver Disease (AASLD) Annual Meeting San Francisco 2005.

Czaja, AJ and Norman, GL. Autoantibodies in the Diagnosis of Liver Disease. J. Clin. Gastro. 2003, 37(4): 315-329.

Czaja, A.J., Shums, Z.,and Norman. G.L. Frequency and Significance of Antibodies to Soluble Liver Antigen/Liver Pancreas in Variant Autoimmune Hepatitis. Autoimmunity 35(8): 475-483, 2002.

Recuero ML, Silva JB, Norman GL, von Muhlen CA, Staub HL. IgA antibodies to beta2-glycoprotein I and carotid disease. Isr Med Assoc J. 2007 Jun;9(6):495-6.

Franck, M, Norman, GL, von Muhlen, et al. Autoantibodies to the atheroma component beta2-glycoprotein 1 and risk of symptomatic peripheral artery disease. Angiology. 2007 Jun-Jul;58(3):295-302.

Iverson, GM, von Muhlen, CA, Staub, HL, Lassen, AJ, Binder, WL, and Norman, GL. Patients with Atherosclerotic Syndrome, negative in anti-cardiolipin assays, make IgA autoantibodies that preferentially target domain 4 of beta2-GPI. J. Autoimmunity 2006; 27:266-271. International Congress of Autoimmunity, Sorrento Italy 2006.

Staub, HL, Franck, M, Ranzolin, A, Norman, GL, Iverson, GM, and von Muhlen, CA. IgA Antibodies to beta2-glycoprotein 1 and Atherosclerosis. Autoimmunity Reviews, 2006.

Lottermann, A, Ranzolin, A. Norman, GL, Bodanese, LC, von Muhlen, CA, Staub, HL. Anticorpos contra as proteinas de choque termico de 60/65 kDa e risco de infarto agudo do miocardio. J. Bras Patol Med Lab 2004; 40; 379-382.

Staub, HL, von Muhlen, CA Norman, GL. Beta-2 glycoprotein 1 IgA antibodies and ischaemic stroke. Rheumatology 2006 45(5): 645-6.

Franck, M, Norman, GL, von Muhlen, CA, Staub, HL. Antibodies to the 60/65 kDa heat-shock proteins and risk of peripheral artery disease. Clinics. 2005 Aug; 60(4); 351-2.

Ranzolin, A, Bohn, JM, Norman, GL, Manenti, E, Bodanese, LC, von Muhlen, CA, Staub, HL. Anti-beta2glycoprotein 1 antibodies as risk factors for acute myocardial infarction. Arq. Bras. Cardiol. 2004 Aug; 83(2): 141-4; 137-40.

Staub, HL, Norman GL, Crowther, TM, Cunha, VR, Polanczk, A, Bohn, JM, Fernandes JG, Chahade, WH, von Muhlen, CA,. Antibodies to the Atherosclerotic Plaque: Components Beta2-glycoprotein 1 and Heat-Shock Proteins as Risk Factors for Acute Cerebral Ischemia. Arq Neuropsiquiatr 2003, 61(3-B): 757-763.

Lewis,S, Keil,LB, Binder,WL, and Debari,VA. Standardized Measurement of Major Immunoglobulin Class (IgG, IgA and IgM) Antibodies to B2 Glycoprotein 1 in Patients With Antiphospholipid Syndrome. Journal Of Clinical Laboratory Analysis. 12:293-297. 1998.

Binder,WL. The anticardiolipin ELISA test. American Clinical Laboratory October 1992.

Santiago M, Baron M, Hudson M, Burlingame RW, Fritzler MJ. Antibodies to RNA polymerase III in systemic sclerosis detected by ELISA. J Rheumatol. 34:1528-34, 2007
http://www.jrheum.com/abstracts/abstracts07/1528.html

Burlingame RW and Peebles C. Detection of Autoantibodies. Autoantibodies and Autoimmunity. Ed. KM Pollard, Wiley-VCH Verlag GmbH and Co., Weinheim, Germany: 159-88, 2006.

Chan EKL, Burlingame RW, Fritzler MJ. Detection of Autoantibodies using immobilized natural and recombinant autoantigens. Systemic Autoimmune Diseases, eds. ASM Press, Washington, DC: 2006.

Gomez-Puerta JA, Burlingame RW, Cervera R. Anti-chromatin (anti-nucleosome) antibodies. Lupus 15: 408-11, 2006.

Williams RC Jr, Harmon ME, Burlingame R, Du Clos TW. Studies of serum C-reactive protein in systemic lupus erythematosus. J Rheumatol 32: 454-61, 2005.

Burlingame,RW. Recent advances in understanding the clinical utility and underlying cause of antinucleosome (anti-chromatin) autoantibodies. Clinical and Applied Immunology Reviews 4 (2004) 351-366.

Martins, T. B., R. Burlingame, C.A. von Muhlen, T.D. Jaskowski, C.M. Litwin and H.R.Hill. Evaluation of multiplexed fluorescent microsphere immunoassay for detection of autoantibodies to nuclear antigens. Clin Diagn Lab Immunol 11: 1054-1059, 2004.
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=524771

Burlingame,RW. The Clinical Utility Of AntiHistone Antibodies. Autoantibodies Reactive with Chromatin in Systemic Lupus Erythematosus and Drug-Induced Lupus. Clinics In Laboratory Medicine Vol 17. No 3. September 1997.

Burlingame, R.W. Recent advances in understanding the clinical utility and underlying cause of antinucleosome (antichromatin) autoantibodies. Clin Appl Immunol Rev 4: 351-366, 2004.

Czaja, A.J., Shums, Z, Binder WL, Lewis SJ, Nelson VJ, and Norman, GL. Frequency and Significance of antibodies to chromatin in autoimmune hepatitis type 1. Dig.Dis.Sci.2003, 48(8): 1658-1664.

Cervera, R., O. Vinas, M. Ramos-Casals, J. Font, M. Garcia-Carrasco, A. Siso, F. Ramirez, Y. Machuca, J. Vives, M. Ingelmo and R.W. Burlingame. Anti-chromatin antibodies in systemic lupus erythematosus: a useful marker for lupus nephropathy. Ann Rheum Dis 62: 431-434, 2003.

Burlingame,RW, Cervera,R. Anti-chromatin (anti-nucleosome) autoantibodies. Autoimmunity Reviews 1 (2002) 321-328.

Burlingame, R.W. and R.L. Rubin. Enzyme-linked immunosorbent assays for diagnostically important antinuclear antibodies. Manual of Clinical Laboratory Immunology, 6th Edition, Eds. N.R. Rose, E.C. d Macario, J.D. Folds, H.C. Lane and R.M. Nakamura. ASM Press, Washington, DC: 951-960, 2002.

Burlingame, R.W. Contributing editor, immunology, biochemistry and genetics, The American Heritage Dictionary, 4rth Edition, Ed. J Pickett, Houghton-Mifflin Co., Boston, MA: 2000.

Burlingame,RW. The Clinical Utility Of AntiHistone Antibodies. Autoantibodies Reactive with Chromatin in Systemic Lupus Erythematosus and Drug-Induced Lupus. Clinics In Laboratory Medicine Vol 17. No 3. September 1997.

Burlingame,RW, Boey,ML, Starkebaum, G, and Rubin, RL. The Central Role of Chromatin in Autoimmune Responses to Histones and DNA in Systemic Lupus Erythematosus. The American Society for Clinical Investigation, Inc. Vol 94, July 1994,184-192.

Burlingame,RW, and Rubin,RL. Drug-induced Anti-Histone Autoantibodies Display Two Patterns of Reactivity with Substructures of Chromatin. The American Society for Clinical Investigation Inc. Vol 88, August 1991,680-690.

Nakmura,RM, Binder, WL. Current Concepts and Diagnostic Evaluation of Autoimmune Disease. Archives of Pathology and Laboratory Medicine. September 1988 Vol 112: 869-877. Copyright 1988. American Medical Association.

Papp, M, Altorjay I, Norman, GL, Shums, Z, Palatka, K, Vitalis Z, Foldi I, Lakos, G, Tumpek, J, Udvasrdy ML, Harsfalvi J, Fischer S, Lakatos L, Kovacs A, Bene L, Molnar R, Tulassay Z, Miheller P, Veres G, Papp J, Lakatos PL. Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/Card15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients.Inflamm Bowel Dis. 2007 Apr 6. Crohn's & Colitis Foundation of America copyright 2007.

Papp, Maria, Norman, GL, Altorjay, I, Lakatos,P.L. Utility of serological markers in inflammatory bowel diseases: Gadget or magic? World J Gastroenterol 2007 April 14; 13(14): 2028-2036.

Ferrante, M, Henckaerts,L, Joossens, M, Pierik,M. Joossens, S, Dotan,N, Norman, GL, Altstock, R, Van Steen,K, Rugeerts, P, Van Assche,G, and Vermeire,S. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut. Published online first: 24 April 2007.

Czaja, AJ, Shums, Z, Norman GL. Nonstandard Antibodies as Prognostic Markers in Autoimmune Hepatitis. Autoimmunity 2004. 37(3): 195-201. American Gastrological Assn. Annual Meeting (DDW) 2004.

Czaja, A.J., Shums, Z., Donaldson, P.T., Norman, GL. Frequency and Significance of Antibodies to Saccharomyces cerevisiae in Autoimmune Hepatitis. Dig.Dis.Sci. 2004; Vol 49(4) 611-618.

Harrer, M, Reinisch, W, Dejaco, C, Kratzer, V., Gmeiner, M, Miehsler, W, Norman, GL, Gangl, A, Vogelsand, H. Do high Serum Levels of Anti-Saccharomyces cerevisiae antibodies (ASCA) result from a Leakyness of the Gut Barrier in Crohn's Disease? European J. Gastroenterology and Hepatalogy. 2003 Dec; 15(12): 1281-5.

Teml, A., Kratzer, V., Schneider, B., Lochs, H., Norman, GL, Gangi, A., Vogelsang, H., Reinisch, W. Anti-Saccharomyces cerevisiae antibodies: A stable marker for Crohn's disease during steroid and 5-aminosalicylic acid treatment. Amer. J. Gastroenterology. 2003, 98(10): 2226-2231.

Prince, H.E., Norman, G.L., and Binder, W.L. IgA deficiency and Alternative Celiac Disease-Associated Antibodies in Sera Submitted to a Reference Laboratory for Endomysial Ig A Testing. Clinical and Diagnostic Immunology. 2000.

Beutner,EH, Baughman,RD, Austin,BM, Plunkett,RW, and Binder, WL. A case of dermatitis herpetiformis with IgA endomysial antibodies but negative direct immunofluorescent findings. Copyright August 2000 by the American Academy of Dermatology Inc. 329-332. J.Am.Acad. Vol 43,No 2 part 2.

Norman, G.L. Anti-Saccharomyces cerevisiae Antibodies in Inflammatory Bowel Disease. Clinical and Applied Immunology Reviews 2: 45-63, 2001.

Norman, GL, Gandhi,Z, Crowther, T, Binder, WL, Kratzer, V, Reinisch, W, and Vogelsang, H. IgG and IgA Anti-Saccharomyces cereivisiae Atibodies (ASCA) Detection by ELISA in Crohn's Disease. Ulcerative colitis, and Healthy Patient Groups., Gastoenterol. 2000; 118(4, suppl 2): A105. American Gastrological Association 2000 Annual Meeting, San Diego, CA May 2000.

Norman, GL, Gandhi, Z, Crowther, T, Binder, WL. A Cytochrome P4502D6 ELISA for Detection of Liver-Kidney Microsomal (LKM-1) Antibodies in Patients and Healthy Patient Groups. Gastroenterol. 2000; 118(4, supl 2): A897. American Association for the Study of Liver Diseases/Digestive Disease Week Meeting (selected as "DDW Poster of Distinction") San Diego, May 2000.

Silveira IG, Burlingame RW, von Muhlen CA, Bender AL, Staub HL. Anti-CCP antibodies have more diagnostic impact than rheumatoid factor (RF) in a population tested for RF. Clin Rheumatol. 2007 Apr 5; [Epub ahead of print].

Santiago M, Baron M, Miyachi K, Fritzler MJ, et al. A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis. Clin Rheumatol. 2007 Jun 15; [Epub ahead of print].

Montano-Loza, A, Czaja, AJ, Carpenter, HA, Piette, AL, Murphy, D, Shums, Z, Burlingame, RW, Norman, GL. Frequency and Significance of Antibodies to Cyclic Citrullinated Peptide in Type 1 Autoimmune Hepatitis. Autoimmunity 2006; 39(4): 341-348. American Assn. For The Study of Liver Disease (AASLD) Annual Meeting Boston 2006.

Burlingame RW. and Williams RC Jr. Reactivity of IgG antibody with cyclic citrullinated peptide occurs through the F(ab)'2 part of the Ig molecule. J Rheumatol 32: 964-5, 2005.

Joossens, S, Daperno, M, Shums, Z, Van Steen K, Goeken, JA, Trapani, C, Norman, GL, Godefridis, G. Caessens, G, Pera, A, Pierik, M, Vermeire, S, Rugeerts, P, Bossuyt, X. Interassay and interobserver variability in the detection of anti-neutrophil cytoplasmic antibodies in patients with ulcerative colitis. Clin Chem; 2004 Aug; 50(8): 1422-5.

Binder,WL. Antineutrophil cytoplasmic antibody (ANCA) and the diagnosis of systemic vasculitis. American Clinical Laboratory May 1992.